Latest news with #ZoetisPharmaceuticalResearchPvtLtd
Time of India
20-05-2025
- Business
- Time of India
Pfizer Q4 results: Net profit jumps 85% to Rs 330.94 crore
NEW DELHI: US pharmaceutical giant Pfizer reported an 85% surge in net profit, reaching Rs 330.94 crore during the fourth quarter ending March 2025, driven by exceptional gains from completed asset sales and transfers, the company said in a regulatory filing. The company had posted a net profit of Rs 178.86 crore in the corresponding quarter of preceding fiscal, Pfizer Ltd said in the filing. Operational revenue reached Rs 591.91 crore in the quarter under review, compared to Rs 546.63 crore in the same period last year, it added. The fourth quarter's total expenses increased to Rs 383.5 crore, up from Rs 377.9 crore in the previous year's corresponding period. The quarter included an exceptional gain of Rs 172.81 crore, resulting from the completed transfer and sale of Thane property, including structures and buildings, to Zoetis Pharmaceutical Research Pvt Ltd. For the fiscal year ending March 31, 2025, the consolidated net profit reached Rs 767.6 crore, compared to Rs 551.33 crore in FY24. The company's operational revenue for FY25 totalled Rs 2,281.35 crore, versus Rs 2,193.17 crore in FY24. The board of directors has proposed a total dividend of Rs 165 per equity share at Rs 10 each for the financial year ending March 2025. The dividend comprises a final dividend of Rs 35 per share, a special dividend of Rs 100 per share marking the company's 75th year in India, and an additional special dividend of Rs 30 per share reflecting gains from the leasehold land and building transfer. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
20-05-2025
- Business
- Time of India
Pfizer Q4 Results: Net profit jumps 85% to Rs 331 cr
Pfizer Ltd has reported an 85 per cent jump in net profit at Rs 330.94 crore in the fourth quarter ended March 2025, boosted by a gain in exceptional item from completion of asset sale and transfer. The company had posted a net profit of Rs 178.86 crore in the corresponding quarter of preceding fiscal, Pfizer Ltd said in a regulatory filing. Revenue from operations in the quarter under review stood at Rs 591.91 crore as against Rs 546.63 crore in the year-ago period, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas In Dubai | Search Ads Get Quote Undo Total expenses in the fourth quarter were higher at Rs 383.5 crore as compared to Rs 377.9 crore in the corresponding period a year ago. During the reporting quarter the company had an exceptional item gain of Rs 172.81 crore from the completion of the transfer and sale of land at Thane along with structures and buildings to Zoetis Pharmaceutical Research Pvt Ltd, the filing said. In the fiscal ended March 31, 2025 consolidated net profit was at Rs 767.6 crore as compared to Rs 551.33 crore in FY24. Live Events In FY25 revenue from operations stood at Rs 2,281.35 crore as compared to Rs 2,193.17 crore in FY24. Pfizer Ltd said its board of directors have recommended a total dividend of Rs 165 per equity share at Rs 10 each for the financial year ended March 2025. This includes a final dividend of Rs 35 per share, a special dividend of Rs 100 per share in view of the company's 75th year in India and a special dividend of Rs 30 per share in view of the gain on transfer of assignment of leasehold land and building, the filing said.
